(a) Results from univariate analyses |
| | ALZ or CLA | 0.27
(0.06, 1.28) | . | . | . | 1.29
(0.24, 6.90) | 1.07
(0.41, 2.80) | . |
| 0.83
(0.30, 2.27) | Anti-CD20 agents | 3.11
(0.75, 12.94) | 2.56
(0.91, 7.20) | 0.70
(0.17, 2.98) | 2.86
(1.21, 6.77) | 1.32
(0.84, 2.07) | 0.77
(0.18, 3.24) | 2.40
(0.43, 13.3) | 2.90
(0.70, 12.03) | DMF | 0.82
(0.15, 4.52) | 0.23
(0.03, 1.64) | 1.33
(0.19, 9.47) | 0.55
(0.13, 2.43) | 0.25
(0.03, 1.78) | 1.71
(0.51, 5.69) | 2.07
(0.94, 4.54) | 0.71
(0.15, 3.45) | FNG | 0.28
(0.05, 1.53) | 1.61
(0.29, 8.84) | 0.74
(0.34, 1.60) | 0.30
(0.05, 1.66) | 0.62
(0.17, 2.17) | 0.74
(0.31, 1.82) | 0.26
(0.05, 1.32) | 0.36
(0.12, 1.08) | NTZ | 5.85
(0.81, 42.25) | 1.97
(0.85, 4.56) | 1.09
(0.15, 7.94) | 2.62
(0.77, 8.83) | 3.17
(1.38, 7.25) | 1.09
(0.22, 5.47) | 1.53
(0.52, 4.50) | 4.25
(1.34, 13.46) | No DMT | 0.39
(0.17, 0.92) | 0.19
(0.03, 1.34) | 1.17
(0.45, 3.02) | 1.41
(0.92, 2.17) | 0.49
(0.11, 2.06) | 0.68
(0.32, 1.45) | 1.90
(0.82, 4.38) | 0.45
(0.19, 1.02) | Platform therapy | 0.45
(0.10, 1.99) | 0.59
(0.11, 3.33) | 0.72
(0.17, 3.01) | 0.25
(0.03, 1.78) | 0.35
(0.07, 1.70) | 0.96
(0.19, 5.00) | 0.23
(0.04, 1.15) | 0.51
(0.12, 2.18) | TRF |
|
|
(b) Results from multivariate analyses |
| | ALZ or CLA | . | . | . | . | . | 3.78
(0.79, 18.00) | . |
| 1.88
(0.33, 10.73) | Anti-CD20 agents | 3.25
(1.46, 7.24) | . | . | 0.91
(0.39, 2.12) | 1.27
(0.31, 5.13) | . | 3.64
(0.65, 20.46) | 1.88
(0.33, 10.73) | DMF | 0.87
(0.37, 2.05) | 0.71
(0.30, 1.69) | 1.07
(0.40, 2.85) | . | 1.12
(0.44, 2.89) | 3.48
(0.59, 20.33) | 3.64
(0.65, 20.46) | 0.96
(0.48, 1.90) | FNG | . | 0.68
(0.16, 2.82) | 0.94
(0.25, 3.57) | . | 2.19
(0.38, 12.49) | 3.48
(0.59, 20.33) | 0.60
(0.32, 1.14) | 0.63
(0.27, 1.49) | NTZ | 1.27
(0.51, 3.19) | 2.25
(0.60, 8.42) | . | 2.59
(0.47, 14.12) | 2.19
(0.38, 12.49) | 0.71
(0.41, 1.23) | 0.75
(0.35, 1.57) | 1.18
(0.62, 2.25) | No DMT | 1.69
(0.66, 4.38) | 0.65
(0.15, 2.92) | 3.78
(0.79, 18.00) | 2.59
(0.47, 14.12) | 1.04
(0.50, 2.18) | 1.09
(0.48, 2.49) | 1.73
(0.80, 3.76) | 1.46
(0.75, 2.84) | Platform therapy | . | 3.18
(0.49, 20.81) | 3.78
(0.79, 18.00) | 0.87
(0.39, 1.97) | 0.91
(0.32, 2.58) | 1.46
(0.54, 3.94) | 1.23
(0.50, 2.99) | 0.84
(0.30, 2.39) | TRF |
|
|
On the upper triangle, the effect size are direct comparisons; the effect sizes presented on lower triangle are network meta-analyses (indirect comparison). Comparisons should be read from left to right (example for upper triangle: OR (95% CI) of developing COVID-19 in anti-CD20 agents compared to DMF is 3.25 (1.46, 7.24); example for lower triangle: OR (95% CI) of developing COVID-19 in the ALZ or CLA group compared to anti-CD20 agents is 1.88 (0.33, 10.73). Platform therapy: interferon and glatiramer acetate; anti-CD20 agents: rituximab and ocrelizumab. ALZ: alemtuzumab; CLA: cladribine; DMF: dimethyl fumarate; FNG: fingolimod; NTZ: natalizumab; TRF: teriflunomide; DMT: disease-modifying therapy.
|
